Immunovia Ab · OMXSTO:IMMNOV
Immunovia Ab — Q2 2025 Earnings Presentation
21 slides from Immunovia Ab's earnings presentation, Aug 28, 2025
Slide 1: 1
1
Slide 2: Q&A session and material Forward looking statements
Q&A session and material Forward looking statements • IMPORTANT: The following applies to this document, the oral presentation of the information in this • Questions can be raised via the chat document by Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any function or
Slide 3: Immunovia's mission is to increase pancreatic cancer survival through early detection
Immunovia’s mission is to increase pancreatic cancer survival through early detection in high-risk individuals and we have never been closer to achieving our mission
Slide 4: Agenda
AGENDA 1 Q2 milestones and progress 2 Q2 financial results 3 Shareholder rights issue 4 PancreaSure test launch 4
Slide 5: Key opinion leaders responded enthusiastically to PancreaSure data at Digestive Disease Week
Key opinion leaders and top clinicians responded enthusiastically to PancreaSure data at Digestive Disease Week, where the CLARITI study was recognized as Best of DDW
Slide 6: Our analytical validation study was honored
Our analytical validation study was honored with a Distinguished Abstract Award by the Academy of Diagnostics & Laboratory Medicine (ADLM)
Slide 7: We made important progress toward payer reimbursement in Q2
We made important progress toward payer reimbursement in Q2 CODE COST COVERAGE Secured a CPT code for Made a pricing Designed clinical Pancreasure. Necessary recommendation to utility studies needed to submit claims for Medicare to secure a to seek coverage from payment rate on the Clinical Medicare
Slide 8: Q2 Financial Results / Shareholder Rights Issue
Q2 FINANCIAL RESULTS SHAREHOLDER RIGHTS ISSUE
Slide 9: Cash balance and cash burn
Cash balance and cash burn • Operating expenses during Q2 2025 were 20 MSEK, which is 17% lower compared to same period last year • Cash balance was 29,3 MSEK as of end Q2 • Cash burn was 6 MSEK per month during Q2 2025, well below guidance of 8-10 MSEK per month • Cash burn expected to be 8-10 MSEK
Slide 10: Shareholder rights issue
Shareholder rights issue • Issue size: 100 MSEK • Guaranteed level: 80% (80 MSEK) • Strong insider participation • Issue announced August 27 2025 • Seeking shareholder approval at an EGM on September 29 2025 • Subscription period: October 7—21 2025
Slide 11: PancreaSure Test Launch
PancreaSure Test Launch
Slide 12: The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance
“The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance. We have long recognized the need for blood-based tests to accurately detect early-stage pancreatic cancer in high-risk individuals and we are excited to offer this test in our program.” Bryson Katona, MD D
Slide 13: PancreaSure Launch Strategy
Start at the top: Build advocacy and use among KOLs and top PancreaSure high-risk surveillance centers Launch Strategy Tie investment to revenue: Execute a highly targeted, low-cost launch leveraging current resources and Immunovia’s strengths. Increase investment as reimbursement grows Position for
Slide 14: We will intentionally ramp our investment in driving volume as payer coverage nears
We will intentionally ramp our investment in driving volume as payer coverage nears Phase TARGETED ADVOCACY VOLUME BUILDING REVENUE GROWTH Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27 Q3 27 Physician GI Groups, Pancreatologists KOLs & HRSCs Gastroenterologists & Other Targets Targets & Endoscopis
Slide 15: Our key metrics will evolve as we move through the three phases of the launch
Our key metrics will evolve as we move through the three phases of the launch Phase TARGETED ADVOCACY VOLUME BUILDING REVENUE GROWTH Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27 Q3 27 Key Metrics Primary: Primary: Number of high-risk surveillance centers PancreaSure volume Primary: PancreaSure re
Slide 16: People at risk for pancreatic cancer often ask if there is a blood test
“People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able detect pancreatic
Slide 17: Seven top pancreatic cancer centers will implement the PancreaSure test at launch
Seven top pancreatic cancer centers will implement the PancreaSure test at launch, with more to come soon 17
Slide 18: Pancreatic cancer is so lethal because it's usually diagnosed too late
“Pancreatic cancer is so lethal because it’s usually diagnosed too late. We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.” Rosario Ligest
Slide 19: Follow our progress on LinkedIn
Follow our progress on LinkedIn: www.linkedin.com/company/immunovia-ab/ www.linkedin.com/in/jeff-borcherding/
Slide 20: Questions
#simmunovia a » 5 > Questions
Slide 21: Seven top pancreatic cancer centers will implement the PancreaSure test at launch
Seven top pancreatic cancer centers will implement the PancreaSure test at launch 21